San Francisco, 25 September 2025: The Report NGS-based RNA-sequencing Market (2025 - 2030) Size, Share & Trends Analysis Report By Product & Service (Consumables, Instruments, Services), By Workflow (Pre-sequencing, Sequencing, Data Analysis), By Application, By End Use, By Region, And Segment Forecasts

The global NGS-based RNA-sequencing market size is expected to reach USD 10.05 billion by 2030 and is anticipated to grow at a CAGR of 17.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is attributed to rising demand for precision medicine, advancements in sequencing technologies, and increasing applications in diagnostics, drug discovery, and disease research. Expanding bioinformatics capabilities and declining sequencing costs further support widespread market adoption.

The COVID-19 pandemic has accelerated the adoption of NGS-based RNA-sequencing owing to its critical role in understanding viral mutations, host response, and pathogen transcriptomics. The urgent need for advanced genomic tools in vaccine and therapeutic development highlighted the value of RNA-sequencing, driving rapid integration into research and public health efforts. This shift has reinforced its importance in infectious disease monitoring and preparedness.

In addition, advancements in high-throughput sequencing technologies have significantly enhanced the speed, accuracy, and scalability of RNA-sequencing. These innovations enable more comprehensive transcriptome profiling, reduce turnaround times, and lower costs, making NGS-based RNA sequencing more accessible for both research and clinical applications.

However, high initial costs associated with sequencing platforms and infrastructure, and ethical concerns surrounding genomic data usage are expected to hamper market growth. These challenges may limit adoption, particularly in resource-constrained settings and regions with stringent data privacy regulations.

The market's growth is fueled by the increasing adoption of precision medicine, rising demand for transcriptome profiling, and advancements in high-throughput sequencing technologies. Additional drivers include expanding applications in biomarker discovery, drug development, and disease diagnostics. The decreasing cost of sequencing and growing investments in genomic research further accelerate the market’s expansion across clinical and research domains.

Request sample report of NGS-based RNA-sequencing Market@ https://www.grandviewresearch.com/industry-analysis/ngs-based-rna-sequencing-market-report/request/rs1

The COVID-19 pandemic positively impacted the NGS-based RNA-sequencing market by accelerating demand for genomic surveillance and virus tracking. NGS technologies, including RNA-seq, were critical in identifying viral mutations, supporting vaccine development, and enhancing diagnostic accuracy. The heightened global focus on infectious disease research increased sequencing infrastructure and innovation investments. This application surge expanded the market’s footprint during the pandemic. It paved the way for broader adoption of RNA-seq in clinical, pharmaceutical, and research settings in the post-pandemic landscape.

In addition, the rising demand for precision and personalized medicine is significantly driving the adoption of NGS-based RNA-sequencing technologies. These solutions enable deeper insights into gene expression and disease mechanisms, allowing for more targeted therapies and improved patient outcomes. As healthcare systems shift towards individualized treatment approaches, RNA-seq is essential for clinical decision-making and tailored therapeutic strategies.

Moreover, growing applications in biomarker discovery and drug development fuel market growth. NGS-based RNA-sequencing enables high-resolution gene expression analysis, facilitating the identification of novel biomarkers and therapeutic targets. This accelerates the drug discovery process, enhances clinical trial efficiency, and supports the development of more effective, targeted treatments, making RNA-seq a critical component in modern pharmaceutical and biotech research pipelines.

The NGS-based RNA-sequencing industry is set for exponential growth, driven by rising demand for precision medicine, advancements in sequencing technologies, and expanding applications in diagnostics and drug development. Increasing research in transcriptomics and biomarker discovery and declining sequencing costs further accelerate market adoption across clinical and pharmaceutical sectors.

The NGS-based RNA-sequencing industry is growing steadily, with moderate collaboration among industry players. Key drivers include the rising need for personalized medicine, advancements in high-throughput sequencing, and increasing use in disease research and drug discovery. Continued investments in genomics and bioinformatics are also enhancing data interpretation, supporting broader adoption across clinical and research applications.